SNCA, MAPT, and GSK3B in Parkinson disease: A gene-gene interaction study

European Journal of Neurology

Volumn 18, Issue 6, 2011, Pages 876-881

  Wider, C ^a,b   Vilarino Guell C ^a   Heckman, M G ^c   Jasinska Myga, B ^a,d   Ortolaza Soto, A I ^a   Diehl, N N ^c   Crook, J E ^c   Cobb, S A ^a   Bacon, J A ^a   Aasly, J O ^e   Gibson, J M ^f   Lynch, T ^g   Uitti, R J ^c   Wszolek, Z K ^c   Farrer, M J ^a   Ross, O A ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c MAYO CLINIC   (United States)

^d MEDICAL UNIVERSITY OF SILESIA   (Poland)

^e NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^f ROYAL VICTORIA HOSPITAL   (United Kingdom)

^g MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Gene gene interaction; Genetics; GSK3B; MAPT; Parkinson disease; SNCA

Indexed keywords

ALPHA SYNUCLEIN; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEIN MAPT; TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CAUCASIAN; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; CASE-CONTROL STUDIES; EPISTASIS, GENETIC; FEMALE; GENETIC VARIATION; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RISK ASSESSMENT; TAU PROTEINS; YOUNG ADULT;

EID: 79955741094     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.03297.x     Document Type: Article

References (18)

1. Lesage S, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 2009; 18: R48-R59.
2. Simon-Sanchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009; 41: 1308-1312.
3. Wider C, Vilarino-Guell C, Jasinska-Myga B, et al. Association of the MAPT locus with Parkinson's disease. Eur J Neurol 2009; 17: 483-486.
4. Winkler S, Hagenah J, Lincoln S, et al. alpha-Synuclein and Parkinson disease susceptibility. Neurology 2007; 69: 1745-1750.
5. Satake W, Nakabayashi Y, Mizuta I, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 2009; 41: 1303-1307.
6. Dickson DW. Tau and synuclein and their role in neuropathology. Brain Pathol 1999; 9: 657-661.
7. Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998; 393: 702-705.
8. Rademakers R, Melquist S, Cruts M, et al. High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. Hum Mol Genet 2005; 14: 3281-3292.
9. Pittman AM, Myers AJ, Abou-Sleiman P, et al. Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet 2005; 42: 837-846.
10. Giasson BI, Forman MS, Higuchi M, et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 2003; 300: 636-640.
11. Galpern WR, Lang AE. Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol 2006; 59: 449-458.
12. Goris A, Williams-Gray CH, Clark GR, et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol 2007; 62: 145-153.
13. Kwok JB, Hallupp M, Loy CT, et al. GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann Neurol 2005; 58: 829-839.
14. Garcia-Gorostiaga I, Sanchez-Juan P, Mateo I, et al. Glycogen synthase kinase-3 beta and tau genes interact in Parkinson's and Alzheimer's diseases. Ann Neurol 2009; 65: 759-761; author reply 761-752.
15. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004; 29: 95-102.
16. Duka T, Duka V, Joyce JN, Sidhu A. Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models. FASEB J 2009; 23: 2820-2830.
17. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56: 33-39.
18. Mamah CE, Lesnick TG, Lincoln SJ, et al. Interaction of alpha-synuclein and tau genotypes in Parkinson's disease. Ann Neurol 2005; 57: 439-443.